ImmunityBio (IBRX) Current Assets (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Current Assets of $453.0 million for Q1 2026, up 314.93% year-over-year from $109.2 million in Q1 2025, and up 43.85% quarter-over-quarter from $314.9 million in Q4 2025.
ImmunityBio (IBRX) Current Assets (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Current Assets for 13 consecutive years, with $453.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 314.93% year-over-year to $453.0 million; the TTM figure through Mar 2026 stood at $453.0 million (up 314.93% YoY), while the FY2025 annual figure was $314.9 million, up 70.58% from the prior year.
- Current Assets grew to $453.0 million in Q1 2026 per IBRX's latest filing, from $314.9 million in the prior quarter.
- Across five years, Current Assets topped out at $453.0 million in Q1 2026 and bottomed at $66.8 million in Q2 2023.
- Historically, Current Assets has averaged $206.0 million across 5 years, with a median of $195.7 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets slumped 57.95% — and 2026, when it jumped 314.93%.
- ImmunityBio's Current Assets stood at $140.6 million in 2022, then jumped by 109.2% to $294.1 million in 2023, then plunged by 37.23% to $184.6 million in 2024, then jumped by 70.58% to $314.9 million in 2025, then jumped by 43.85% to $453.0 million in 2026.
- Business Quant data shows IBRX's Current Assets at $453.0 million in Q1 2026, $314.9 million in Q4 2025, and $329.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 438.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 438.98 Mn |
| Mar 31, 2026 | 452.95 Mn |
| Dec 31, 2025 | 314.88 Mn |
| Sep 30, 2025 | 329.50 Mn |
| Jun 30, 2025 | 208.13 Mn |
| Mar 31, 2025 | 109.16 Mn |
| Dec 31, 2024 | 184.59 Mn |
| Sep 30, 2024 | 163.15 Mn |
| Jun 30, 2024 | 242.83 Mn |
| Mar 31, 2024 | 195.72 Mn |
| Dec 31, 2023 | 294.08 Mn |
| Sep 30, 2023 | 215.08 Mn |
| Jun 30, 2023 | 66.83 Mn |
| Mar 31, 2023 | 113.49 Mn |
| Dec 31, 2022 | 140.58 Mn |
| Sep 30, 2022 | 143.09 Mn |
| Jun 30, 2022 | 114.99 Mn |
| Mar 31, 2022 | 212.34 Mn |
| Dec 31, 2021 | 334.35 Mn |
| Sep 30, 2021 | 94.45 Mn |